Efalizumab (Raptiva™) is no longer available. It was withdrawn from the market in 2009. This information page is of historical interest only.
Efalizumab belongs to the class of biological response modifiers called T-cell blockers. It is an effective treatment in patients with moderate to severe plaque psoriasis.
Efalizumab is a genetically modified form of mouse protein that is directed at blocking T cell activation and proliferation by binding to CD11a receptors on T cells. This stops the T cells from releasing cytokines, which are the primary cause of the inflammation, redness, itching and flaky skin patches characteristic of psoriasis.
Initial trials of efalizumab involved intravenous (IV) administration of the drug. However, a subcutaneous (SC) formulation has been developed and is currently being used. Once weekly dosing for a 12-week period improves psoriasis to some degree in about 50% of patients.
Improvements in psoriasis made after 12 weeks of treatment can be maintained with further weekly doses or every-other week dosing.
Efalizumab appears to be well tolerated. The most frequently reported side effects included headache, nausea, chills, pain, fever and non-specific infection such as the common cold. These occurred most often after the first injection and became less with subsequent doses.
Efalizumab is an immune supressing agent and so increases susceptibility to infections.
WARNING: 9 April 2009. Genetech decided to voluntarily withdraw efalizumab (Raptiva) from the US market due to a potentially increased risk of progressive multifocal leukoencephalopathy (PML).
19 February 2009. The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research has issued a Public Health Advisory Updated Safety Information about Raptiva (efalizumamb) because of four reports of patients taking this drug that developed the rare life-threatening brain infection, Progressive Multifocal Leukoencephalopathy (PML) and other infections.
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).
